| Ytd | -24.14% | |
| 1y | -6.33% |
| Open | 304.54 | Prev Close | 301.03 | Low | 301.50 | High | 309.27 | Mkt Cap | 40.28B |
| Vol | 1.04M | Avg Vol | 1.14M | EPS | 3.98 | P/E | 75.80 | Forward P/E | 22.22 |
| Beta | 0.27 | Short Ratio | 5.14 | Inst. Own | 102.05% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-30 | 50-d Avg | 295.74 | 200-d Avg | 367.67 | 1yr Est | 434.72 |
ALNY News
Top Wall Street analysts upgraded and downgraded several top companies, including Applied Materials,
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALN
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare
Expanded agreement extends Marmot across key enterprise functions, advancing a new operating model f
NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Komodo Health®, the leader in AI-powered healthcare
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 10 years by 3.79% on
GENESIS Pharma, a leading regional biopharma company focused on the commercialization of innovative
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:AL
Alnylam stock rises after a $2 billion AI-driven RNAi drug discovery collaboration with Inceptive as
− Collaboration is valued at up to $2B with upfront consideration of $30M −− Alliance pairs Alnylam&